

C5 β (D-14): sc-14619

BACKGROUND

C3a, C4a and C5a are potent anaphylatoxins that are released during complement activation, a system of ligand-surface protein interactions specific to cells of hematopoietic lineage that aids in the elimination of pathogens. Complement C5 precursor contains C5a anaphylatoxin. C3a and C5a secretion correlates with pathophysiological phenotypes such as asthma and bacterial meningitis. Binding of these proteins to their respective G protein-coupled receptors (C3aR, C5aR), which are present on the surface of myeloid leukocytes, induces proinflammatory events such as cellular degranulation, smooth muscle contraction, arachidonic acid metabolism, cytokine release, leukocyte activation and cellular chemotaxis. C5aR utilizes the Ras-Raf-ERK1/2 cascade, couples to G_i/G₁₆ proteins, and is prevalent on the surface of hepatocyte, lung, smooth muscle and endothelial cells. Upon activation, C3aR and C5aR are susceptible to rapid GRK-mediated phosphorylation and Clathrin-coated vesicle targeting. The C5 precursor is first processed by the removal of four basic residues, forming two chains, β and α , linked by a disulfide bond. C5 convertase activates C5 by cleaving the α chain, releasing C5 α anaphylatoxin and generating C5 β .

REFERENCES

1. de Bruijn, M.H. and Fey, G.H. 1985. Human complement component C3: cDNA coding sequence and derived primary structure. *Proc. Natl. Acad. Sci. USA* 82: 708-712.
2. Buhl, A.M., Osawa, S. and Johnson, G.L. 1995. Mitogen-activated protein kinase activation requires two signal inputs from the human anaphylatoxin C5a receptor. *J. Biol. Chem.* 270: 19828-19832.
3. Stahel, P.F., Frei, K., Eugster, H.P., Fontana, A., Hummel, K.M., Wetsel, R.A., Ames, R.S. and Barnum, S.R. 1997. TNF α -mediated expression of the receptor for anaphylatoxin C5a on neurons in experimental *Listeria meningoencephalitis*. *J. Immunol.* 159: 861-869.
4. Langkabel, P., Zwirner, J. and Oppermann, M. 1999. Ligand-induced phosphorylation of anaphylatoxin receptors C3aR and C5aR is mediated by G protein-coupled receptor kinases. *Eur. J. Immunol.* 29: 3035-3046.
5. Settmacher, B., Bock, D., Saad, H., Gartner, S., Rheinheimer, C., Kohl, J., Bartsch, W. and Klos, A. 1999. Modulation of C3a activity: internalization of the human C3a receptor and its inhibition by C5a. *J. Immunol.* 162: 7409-7416.
6. Humbles, A.A., Lu, B., Nilsson, C.A., Lilly, C., Israel, E., Fujiwara, Y., Gerard, N.P. and Gerard, C. 2000. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. *Nature* 406: 998-1001.

CHROMOSOMAL LOCATION

Genetic locus: C5 (rat) mapping to 3p11.

SOURCE

C5 β (D-14) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the N-terminus of C5 β of rat origin.

PRODUCT

Each vial contains 200 μ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-14619 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

C5 β (D-14) is recommended for detection of C5 precursor and C5 β chain of rat origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Molecular Weight of C5 β : 189 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker[™] compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker[™] Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz[™] Mounting Medium: sc-24941.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

MONOS
Satisfaction
Guaranteed

Try **C5 β (E-8): sc-398247**, our highly recommended monoclonal alternative to C5 β (D-14).